newsfilter
← Latest News
GlobeNewswire·

Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

  • Fortress Biotech reported total net revenue of $19.2 million for the third quarter of 2026, an increase of approximately 9% compared to $17.6 million in the same period of 2025.
  • In September 2026, Fortress repaid the full $15.0 million outstanding principal on its senior secured credit facility with Oaktree, leaving the company with no outstanding debt at the parent level.
  • A subsidiary entered an exclusive license agreement with Cedars-Sinai for FB-607, a novel therapy for irritable bowel syndrome with diarrhea currently in a Phase 2 trial with top-line data expected in the second half of 2027.
  • Partner company Journey Medical reported approximately 40,000 prescriptions for its rosacea treatment Emrosi® during the third quarter of 2026, generating $18.9 million in net product revenues.
  • Crystalys Therapeutics closed a $130 million Series B financing in July 2026 to advance dotinurad development, with Fortress holding an equity stake eligible for a 3% royalty on future sales.
  • Anselamimab (formerly CAEL-101) received regulatory approval in Japan in September 2026 for the treatment of systemic kappa light chain amyloidosis.
  • Fortress recognized $0.2 million in royalty revenue from ZYCUBO® sales by Cyprium Therapeutics and $0.1 million in contingent royalty income from UNLOXCYT™ sales during the third quarter.
  • Consolidated cash and cash equivalents increased to $152.2 million as of September 30, 2026, from $79.4 million at the end of 2025.
  • Consolidated research and development expenses rose to $1.7 million for the third quarter of 2026, compared to $0.2 million in the prior year period.
  • Selling, general, and administrative costs totaled $17.8 million for the third quarter of 2026, an increase from $17.4 million in the third quarter of 2025.
  • The company reported a net loss attributable to common stockholders of $(7.9) million, or $(0.23) per share, for the third quarter of 2026, contrasting with a net income of $3.7 million in the same period of 2025.
  • Fortress maintains a portfolio of ongoing clinical trials for Triplex in cytomegalovirus treatment and is exploring a trial for MB-109 in the first quarter of 2027 for glioblastoma patients.
Company
Fortress Biotech, Inc.
Keywords
Nasdaq:FBIO, Fortress Biotech, Inc., Fortress Biotech, FBIO, Financial Results, EARNINGS